WO2006049463A1 - Hemostatic agent internally applied through endoscope and application method thereof - Google Patents

Hemostatic agent internally applied through endoscope and application method thereof

Info

Publication number
WO2006049463A1
WO2006049463A1 PCT/KR2005/003730 KR2005003730W WO2006049463A1 WO 2006049463 A1 WO2006049463 A1 WO 2006049463A1 KR 2005003730 W KR2005003730 W KR 2005003730W WO 2006049463 A1 WO2006049463 A1 WO 2006049463A1
Authority
WO
WIPO (PCT)
Prior art keywords
coating agent
hemostatic agent
agent
mucous membrane
lesion
Prior art date
Application number
PCT/KR2005/003730
Other languages
French (fr)
Inventor
Kun Na
Don Haeng Lee
Original Assignee
Kun Na
Don Haeng Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kun Na, Don Haeng Lee filed Critical Kun Na
Publication of WO2006049463A1 publication Critical patent/WO2006049463A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates

Definitions

  • the present invention relates to a hemostatic agent for internal body use and a method of applying the same inside the human body using an endoscope apparatus. More particularly, the present invention relates to a hemostatic agent for internal body use and a method of applying the same onto a hemorrhagic lesion of the gastrointestinal tract in the human body in an endoscopic stanching manner.
  • Gastrointestinal bleeding is a fairly common medical problem. It has been reported that generally about one hundred people from one hundred thousand people are treated in the hospital for gastrointestinal bleeding every year, and the mortality rate from gastrointestinal bleeding is about 8 to 10%. In about 80% of the cases gastrointestinal bleeding mostly occurs in the upper-gastrointestinal tract. In upper-gastrointestinal bleeding, the bleeding originates in the first part of the gastrointestinal tract, i.e., the esophagus, stomach, or duodenum, and results in haematemesis and melaena. A bleeding site in upper-gastrointestinal bleeding can be easily identified by an endoscopic method. The identification rate in this case is about 90%.
  • Polypectromy, endoscopic mucosal resection, and endoscopic treatment are common treatments to treat stomach cancer or colon cancer. However, during or after such treatments, sometimes bleeding from the stomach or colon occurs, which can require emergency surgical interventions or even lead to the death of the patient.
  • Gastrointestinal bleeding has been treated mainly by surgical interventions.
  • endoscopic hemostatic methods have become the standard treatment for gastrointestinal bleeding.
  • a hypertonic solution epinephrine, or alcohol is directly injected into an ulcer, and then a coagulation therapy using electric heat or laser, or a physical hemostatic method using a clip is used.
  • the conventional bleeding control methods aim at reducing the amount of bleeding by pressing or ligating a vascular tract by injecting a liquid agent into a vascular vessel around an ulcer. Accordingly, the ulcer remains as its mucous membrane is exfoliated. As a result, even after the treatment, the bleeding often continues.
  • the conventional endoscopic hemostatic treatment is successful in only 70 to 80% of the cases. Further, bleeding reoccurs in 20 to 25% of the cases, 3 to 4 days after the endoscopic hemostatic treatment.
  • Rebleeding refers to bleeding from a vascular vessel, and occurs before the ulcer is completely cured by the regeneration of tissue around the ulcer. Thus, it is difficult to be treated by the conventional endoscopic hemostatic method that stops bleeding when the mucous membrane of the ulcer is exfoliated.
  • the conventional endoscopic treatment aims at stopping bleeding, not curing the ulcer. Accordingly, after performing the conventional endoscopic treatment, cure of the ulcer or the lesion is too slow and rebleeding might occur frequently.
  • a hemostatic agent for internal body use and a method of applying the hemostatic agent onto an ulcer inside the human body, in which a coating agent serving as the hemostatic agent is dispersed and coated onto the ulcer in an endoscopic manner to totally stop bleeding from the ulcer and prevent completely rebleeding of the ulcer.
  • a hemostatic agent for internal body use which can be endoscopically applied onto a mucous membrane lesion in the human body in order to stop bleeding from the mucous membrane lesion.
  • the hemostatic agent comprises a coating agent as a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flow through an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds.
  • a method of applying a hemostatic agent inside the human body using an endoscope catheter including (a) inserting an endoscope catheter in the human body and placing a front end of the catheter near a lesion of a mucous membrane!
  • the hemostatic agent is a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flow through an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds.
  • FIG. 1 is a photograph showing an ulcer before treatment with a hemostatic agent for internal body use, according to an embodiment of the present invention
  • FIG. 2 is a photograph showing the ulcer after applying the hemostatic agent thereonto.
  • FIG. 3 is a photograph showing the ulcer 72 hours after the application of the hemostatic agent. [Best Mode]
  • a coating agent having a cationic reaction product in an aqueous solution or a polysaccharide solution includes at least one selected from the group consisting of chitosan, polyricin, polyhistidine, polydiethylaminoethyl, methacrylate, and a combination thereof.
  • a coating agent having an anionic reaction product in an aqueous solution or a polysaccharide solution includes at least one selected from the group consisting of alginate, carrginan, hyaluronic acid, chondroitin sulfate, or a combination thereof.
  • a coating agent having a nonionic reaction product in an aqueous solution or a polysaccharide solution includes at least one selected from the group consisting of cellulose, caccia gum, ploxamer, polyglycol/polylactic acid (PLLA) copolymer, polylactic acid-polyglycolic acid, and a combination thereof.
  • a first coating agent made of a polymer solution containing a cationic reaction product is used together with a second coating agent made of a polymer solution containing an anionic reaction product.
  • the first coating agent may be applied onto a lesion site of a mucous membrane in the human body using an endoscope, and then the second coating agent is applied onto the surface of the first coating agent using the endoscope.
  • each coating agent applied to the ulcer in a stomach or an intestine maintains the adherence with its mucous membrane while having hydrophobic outer surface that is exposed to water or gastric juice. Accordingly, the composition of the coating agent can have a relatively long durability.
  • the coating agents according to the present invention can stop bleeding when they are applied onto an ulcer, and prevent the ulcer from being exposed to gastric juice, thereby protecting the ulcer from secondary infection.
  • the first coating agent is a polymer solution containing a cationic reaction product and the second coating agent is a polymer solution containing an anionic reaction product.
  • the first coating agent directly applied to the interior of a human body can be a polymer solution containing an anionic reaction product and the second coating agent applied onto the surface of the first coating agent can be a polymer solution containing a cationic reaction product.
  • the first coating agent may be preferably a polymer solution containing a cationic reaction product.
  • the coating agent serving as the hemostatic agent according to the embodiment of the present invention may further contain a supplement which will be described in more detail below.
  • the supplement includes a H 2 receptor antagonist, antacid, a hydrogen ion pump inhibitor, a jump defense agonist, and so on.
  • the H2 receptor antagonist is an acid secretion inhibitor, and examples thereof include cimetidine, ranitidine, famotidine, nizatidine, rozatidine, and a combination thereof.
  • Examples of the antacid include calcium carbonate, aluminum hydroxide, magnesium hydroxide, a combination thereof.
  • Examples of the hydrogen ion pump inhibitor (PPI) include omeprazole, rabeprazole, pantoprazole, and a combination thereof.
  • the jump defense agonist includes rebaipide.
  • the coating agent according to an embodiment of the present invention contains the supplements stated above, the coating agent can promote curing of the ulcer by medical effects of the supplements and growth factor and can also stop bleeding from the ulcer.
  • the method according to an embodiment of the present invention includes (a) introducing a catheter into the human body so that a front tip of the catheter reaches a lesion of a mucous membrane, and (b) injecting the hemostatic agent into the human body through an endoscope catheter to apply the hemostatic agent to the lesion of the mucous membrane.
  • the step (b) includes (b ⁇ l) applying a first coating agent made of a polymer solution containing a cationic reaction product to the lesion of the mucous membrane, and (b-2) coating a second coating agent of a polymer solution containing an anionic reaction product on the surface of the first coating agent.
  • ⁇ 33> For the test, 1 to 5 g of chitosan containing a cationic reaction product is introduced into acetic acid (pH 3.0 to 5.5), and then mixed together to be dissolved, thereby preparing a first coating solution. Next, 1 to 10 g of alginate containing an anionic reaction product is introduced into distilled water and mixed together to be dissolved, thereby preparing a second coating solution. The concentration of the coating solutions is determined so that the solutions can flow through an endoscope.
  • the first coating solution is injected through the catheter so that the first coating solution is sprayed onto the ulcer.
  • the second coating solution is injected through the catheter so that the second coating solution is sprayed onto the surface of the first coating solution.
  • FIG. 1 is a photograph showing an ulcer before treatment with a hemostatic agent for internal body use, according to an embodiment of the present invention
  • FIG. 2 is a photograph showing the ulcer after applying the hemostatic agent thereto
  • FIG.3 is a photograph showing the ulcer 72 hours after the application of the hemostatic agent.
  • the hemostatic agent and the method of applying the same inside the human body using an endoscope have the following advantages.
  • the hemostatic agent contains the supplement, the ulcer can be cured by the medical effect and growth factor of the supplement.

Abstract

Provided is a hemostatic agent for internal body use, which can be applied onto a bleeding lesion of the gastrointestinal tract by an endoscopic hemostatic method, and a method of applying the hemostatic agent onto the bleeding lesion. The coating agent is a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution. The coating agent hemostatic agent for stopping bleeding from a lesion of a mucous membrane by being applied onto the lesion of the mucous membrane through an endoscope, comprising a coating agent as a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flowthrough an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds. According to the hemostatic agent and method thereof, since the hemostatic agent is applied onto an ulcer through an endoscope, the ulcer can be completely covered with the hemostatic agent. As a result, bleeding from the ulcer can be totally stopped and there is no major probability of rebleeding. Further, since the hemostatic agent contains the supplement, the ulcer can be cured by the medical effect and growth factor of the supplement.

Description

[DESCRIPTION] [Invention TitIe]
HEMOSTATIC AGENT INTERNALLY APPLIED THROUGH ENDOSCOPE AND APPLICATION METHOD THEREOF [Technical Field]
<i> The present invention relates to a hemostatic agent for internal body use and a method of applying the same inside the human body using an endoscope apparatus. More particularly, the present invention relates to a hemostatic agent for internal body use and a method of applying the same onto a hemorrhagic lesion of the gastrointestinal tract in the human body in an endoscopic stanching manner. [Background Art]
<2> Gastrointestinal bleeding is a fairly common medical problem. It has been reported that generally about one hundred people from one hundred thousand people are treated in the hospital for gastrointestinal bleeding every year, and the mortality rate from gastrointestinal bleeding is about 8 to 10%. In about 80% of the cases gastrointestinal bleeding mostly occurs in the upper-gastrointestinal tract. In upper-gastrointestinal bleeding, the bleeding originates in the first part of the gastrointestinal tract, i.e., the esophagus, stomach, or duodenum, and results in haematemesis and melaena. A bleeding site in upper-gastrointestinal bleeding can be easily identified by an endoscopic method. The identification rate in this case is about 90%.
<3> Polypectromy, endoscopic mucosal resection, and endoscopic treatment are common treatments to treat stomach cancer or colon cancer. However, during or after such treatments, sometimes bleeding from the stomach or colon occurs, which can require emergency surgical interventions or even lead to the death of the patient.
<4> Gastrointestinal bleeding has been treated mainly by surgical interventions. However, recently, endoscopic hemostatic methods have become the standard treatment for gastrointestinal bleeding.
<5> In the endoscopic hemostatic method, a hypertonic solution, epinephrine, or alcohol is directly injected into an ulcer, and then a coagulation therapy using electric heat or laser, or a physical hemostatic method using a clip is used.
<6> However, the conventional bleeding control methods aim at reducing the amount of bleeding by pressing or ligating a vascular tract by injecting a liquid agent into a vascular vessel around an ulcer. Accordingly, the ulcer remains as its mucous membrane is exfoliated. As a result, even after the treatment, the bleeding often continues. According to many research studies, the conventional endoscopic hemostatic treatment is successful in only 70 to 80% of the cases. Further, bleeding reoccurs in 20 to 25% of the cases, 3 to 4 days after the endoscopic hemostatic treatment.
<7> Rebleeding refers to bleeding from a vascular vessel, and occurs before the ulcer is completely cured by the regeneration of tissue around the ulcer. Thus, it is difficult to be treated by the conventional endoscopic hemostatic method that stops bleeding when the mucous membrane of the ulcer is exfoliated.
<8> Also, the conventional endoscopic treatment aims at stopping bleeding, not curing the ulcer. Accordingly, after performing the conventional endoscopic treatment, cure of the ulcer or the lesion is too slow and rebleeding might occur frequently. [Disclosure] [Technical Problem]
<9> To solve the above problems, it is an objective of the present invention to provide a hemostatic agent for internal body use and a method of applying the hemostatic agent onto an ulcer inside the human body, in which a coating agent serving as the hemostatic agent is dispersed and coated onto the ulcer in an endoscopic manner to totally stop bleeding from the ulcer and prevent completely rebleeding of the ulcer.
<io> It is another object of the present invention to provide a hemostatic agent that can be endoscopically applied inside the human body, can stop bleeding of an ulcer, and promote cure of the ulcer, and a method of applying the same inside the human body. [Technical Solution]
<ii> To accomplish the above object of the present invention, there is provided a hemostatic agent for internal body use, which can be endoscopically applied onto a mucous membrane lesion in the human body in order to stop bleeding from the mucous membrane lesion. The hemostatic agent comprises a coating agent as a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flow through an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds.
<12> According to another aspect of the present invention, there is provided a method of applying a hemostatic agent inside the human body using an endoscope catheter, the method including (a) inserting an endoscope catheter in the human body and placing a front end of the catheter near a lesion of a mucous membrane! and (b) injecting the hemostatic agent through the endoscope catheter to apply the hemostatic agent onto the lesion of the mucous membrane, wherein the hemostatic agent is a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flow through an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds.
[Description of Drawings]
<14> FIG. 1 is a photograph showing an ulcer before treatment with a hemostatic agent for internal body use, according to an embodiment of the present invention;
<15> FIG. 2 is a photograph showing the ulcer after applying the hemostatic agent thereonto; and
<i6> FIG. 3 is a photograph showing the ulcer 72 hours after the application of the hemostatic agent. [Best Mode]
<i7> As repeated of experiments, the present inventors have found the following materials could be adopted as coating agents for internal body use according to an embodiment of the present invention.
<i8> A coating agent having a cationic reaction product in an aqueous solution or a polysaccharide solution includes at least one selected from the group consisting of chitosan, polyricin, polyhistidine, polydiethylaminoethyl, methacrylate, and a combination thereof.
<19> A coating agent having an anionic reaction product in an aqueous solution or a polysaccharide solution includes at least one selected from the group consisting of alginate, carrginan, hyaluronic acid, chondroitin sulfate, or a combination thereof.
<2o> A coating agent having a nonionic reaction product in an aqueous solution or a polysaccharide solution includes at least one selected from the group consisting of cellulose, caccia gum, ploxamer, polyglycol/polylactic acid (PLLA) copolymer, polylactic acid-polyglycolic acid, and a combination thereof.
<2i> According to another aspect of the present invention, a first coating agent made of a polymer solution containing a cationic reaction product is used together with a second coating agent made of a polymer solution containing an anionic reaction product. In this case, the first coating agent may be applied onto a lesion site of a mucous membrane in the human body using an endoscope, and then the second coating agent is applied onto the surface of the first coating agent using the endoscope.
<22> By the double-coating, cationic ions of the first coating agent and anionic ions of the second coating agent are bonded by interaction, and a bonded portion becomes hydrophobic. Accordingly, each coating agent applied to the ulcer in a stomach or an intestine maintains the adherence with its mucous membrane while having hydrophobic outer surface that is exposed to water or gastric juice. Accordingly, the composition of the coating agent can have a relatively long durability.
<23> The coating agents according to the present invention can stop bleeding when they are applied onto an ulcer, and prevent the ulcer from being exposed to gastric juice, thereby protecting the ulcer from secondary infection.
<24> In the above embodiment, the first coating agent is a polymer solution containing a cationic reaction product and the second coating agent is a polymer solution containing an anionic reaction product. In the another embodiment of the present invention, however, the first coating agent directly applied to the interior of a human body can be a polymer solution containing an anionic reaction product and the second coating agent applied onto the surface of the first coating agent can be a polymer solution containing a cationic reaction product. However, taking into account that skin of the interior of the human body is charged with negative ions, the first coating agent may be preferably a polymer solution containing a cationic reaction product.
<25> The coating agent serving as the hemostatic agent according to the embodiment of the present invention may further contain a supplement which will be described in more detail below. The supplement includes a H2 receptor antagonist, antacid, a hydrogen ion pump inhibitor, a jump defense agonist, and so on. <26> The H2 receptor antagonist is an acid secretion inhibitor, and examples thereof include cimetidine, ranitidine, famotidine, nizatidine, rozatidine, and a combination thereof. Examples of the antacid include calcium carbonate, aluminum hydroxide, magnesium hydroxide, a combination thereof. Examples of the hydrogen ion pump inhibitor (PPI) include omeprazole, rabeprazole, pantoprazole, and a combination thereof. The jump defense agonist includes rebaipide.
<27> Since the coating agent according to an embodiment of the present invention contains the supplements stated above, the coating agent can promote curing of the ulcer by medical effects of the supplements and growth factor and can also stop bleeding from the ulcer.
<28> Hereinafter, a method of applying the hemostatic agent inside the human body through an endoscope will be described.
<29> The method according to an embodiment of the present invention includes (a) introducing a catheter into the human body so that a front tip of the catheter reaches a lesion of a mucous membrane, and (b) injecting the hemostatic agent into the human body through an endoscope catheter to apply the hemostatic agent to the lesion of the mucous membrane.
<30> In the case in which the double-coating method is used, the step (b) includes (b~l) applying a first coating agent made of a polymer solution containing a cationic reaction product to the lesion of the mucous membrane, and (b-2) coating a second coating agent of a polymer solution containing an anionic reaction product on the surface of the first coating agent.
<3i> The composition of the hemostatic agent used in the above method is the same as that of the homeostatic agent described above. Accordingly, the detailed description of the hemostatic agent will be omitted.
<32> Hereinafter, results from testing the hemostatic agent according to the embodiment of the present invention and the method of applying the hemostatic agent will be described below.
<33> For the test, 1 to 5 g of chitosan containing a cationic reaction product is introduced into acetic acid (pH 3.0 to 5.5), and then mixed together to be dissolved, thereby preparing a first coating solution. Next, 1 to 10 g of alginate containing an anionic reaction product is introduced into distilled water and mixed together to be dissolved, thereby preparing a second coating solution. The concentration of the coating solutions is determined so that the solutions can flow through an endoscope.
<34> After introducing the endoscope catheter into the human body and placing the front end of the catheter at an ulcer, the first coating solution is injected through the catheter so that the first coating solution is sprayed onto the ulcer. Next, the second coating solution is injected through the catheter so that the second coating solution is sprayed onto the surface of the first coating solution.
<35> FIG. 1 is a photograph showing an ulcer before treatment with a hemostatic agent for internal body use, according to an embodiment of the present invention, FIG. 2 is a photograph showing the ulcer after applying the hemostatic agent thereto, and FIG.3 is a photograph showing the ulcer 72 hours after the application of the hemostatic agent.
<36> As apparent from the test results, the coating agent remains on the ulcer even after 72 or more hours after it was applied onto the ulcer, and also the ulcer is almost cured. [Industrial Applicability]
<37> According to the present invention, the hemostatic agent and the method of applying the same inside the human body using an endoscope have the following advantages.
<38> First, since the hemostatic agent is applied onto an ulcer through an endoscope, the ulcer can be completely covered with the hemostatic agent. As a result, bleeding from the ulcer can be totally stopped and there is no major probability of rebleeding.
<39> Second, since the hemostatic agent contains the supplement, the ulcer can be cured by the medical effect and growth factor of the supplement.

Claims

[CLAIMS] [Claim 1]
<4i> A hemostatic agent for stopping bleeding from a lesion of a mucous membrane by being applied onto the lesion of the mucous membrane through an endoscope, comprising:
<42> a coating agent as a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flow through an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds.
[Claim 2]
<43> The hemostatic agent according to claim 1, wherein the coating agent comprises one or more chemicals selected from the cationic polymer group consisting of chitosan, polyricin, polyhistidine, polydiethylaminoethyl, and raethacrylate, the anionic polymer group consisting of alginate, carrginan, hyaluronic acid, and chondroitin sulfate, or the nonionic polymer group consisting of cellulose, caccia gum, ploxamer, polyglycol/polylactic acid (PLLA) copolymer, and polylactic acid/polyglycolic acid.
[Claim 3]
<44> The hemostatic agent according to claim 1, comprising a first coating agent which is directly applied onto the lesion of the mucous membrane and made of a polymer solution containing a cationic reaction product, and a second coating agent which is applied onto the outer surface of the first coating agent and made of a polymer solution containing an anionic reaction product.
[Claim 4]
<45> The hemostatic agent according to claim 1, wherein the coating agent further comprises one or more supplements selected from the group consisting of a H2 receptor antagonist, an antacid, a hydrogen ion pump inhibitor, and a jump defense agonist; <46> wherein the H2 receptor antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, nizatidine, and rozatidine; <47> wherein the antacid is selected from the group consisting of calcium carbonate, aluminum hydroxide, and magnesium hydroxide; <48> wherein the hydrogen ion pump inhibitor (PPI) is selected from the group consisting of omeprazole, rabeprazole, and pantoprazole; and <49> wherein the jump defense agonist comprises rebaipide.
[Claim 5] <50> A method of applying a hemostatic agent inside the human body using an endoscope catheter, comprising: <5i> (a) inserting an endoscope catheter in the human body and placing a front end of the catheter near a lesion of a mucous membrane; and <52> (b) injecting the hemostatic agent through the endoscope catheter to apply the hemostatic agent onto the lesion of the mucous membrane, <53> wherein the hemostatic agent is a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flow through an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds.
[Claim 6]
<54> The method according to claim 5, wherein the step (b) comprises: <55> (b-1) applying a first coating agent made of a polymer solution containing a cationic reaction product onto the lesion of the mucous membrane; and <56> (b-2) applying a second coating agent made of a polymer solution containing an anionic reaction product on the surface of the first coating agent.
PCT/KR2005/003730 2004-11-05 2005-11-04 Hemostatic agent internally applied through endoscope and application method thereof WO2006049463A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040089885A KR20060040329A (en) 2004-11-05 2004-11-05 Hemostatic agent which can be applied via endoscope and applying method of the same
KR10-2004-0089885 2004-11-05

Publications (1)

Publication Number Publication Date
WO2006049463A1 true WO2006049463A1 (en) 2006-05-11

Family

ID=36319426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/003730 WO2006049463A1 (en) 2004-11-05 2005-11-04 Hemostatic agent internally applied through endoscope and application method thereof

Country Status (2)

Country Link
KR (1) KR20060040329A (en)
WO (1) WO2006049463A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124433A1 (en) * 2006-04-20 2007-11-01 Crosslink-D Hemostatic compositions and methods for controlling bleeding
EP2026850A2 (en) * 2006-05-23 2009-02-25 Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
WO2010136872A3 (en) * 2009-05-25 2011-05-26 Pharcoterm S.R.L. Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination
CN103446619A (en) * 2013-08-19 2013-12-18 青岛中腾生物技术有限公司 Novel absorbable hemostatic material
US8951565B2 (en) 2003-12-23 2015-02-10 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan
US9004918B2 (en) 2001-06-14 2015-04-14 Hemcon Medical Technologies, Inc. Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan
US9205170B2 (en) 2008-05-02 2015-12-08 Hemcon Medical Technologies, Inc. Wound dressing devices and methods
US9204957B2 (en) 2005-03-17 2015-12-08 Hemcon Medical Technologies, Inc. Systems and methods for hemorrhage control and or tissue repair
EP2950822A4 (en) * 2013-01-30 2016-10-19 Daewoong Co Ltd Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
US10004690B2 (en) 2014-01-21 2018-06-26 Utah-Inha Dds & Advanced Therapeutics Research Center Administrable microparticles in vivo through medical conduit
US10086105B2 (en) 2008-10-06 2018-10-02 Providence Health System—Oregon Chitosan foam medical devices and methods
WO2021167963A1 (en) * 2020-02-18 2021-08-26 Boston Scientific Scimed, Inc. Hemostatic compositions and related methods

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109529094A (en) * 2018-11-05 2019-03-29 首都师范大学 A kind of efficient hemostatic material and preparation method thereof can promote wound healing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0332677A (en) * 1989-06-30 1991-02-13 Yoshihiko Shimizu Vein closing material for imparting phlogistic and clotting property
US20020010150A1 (en) * 2000-04-28 2002-01-24 Cortese Stephanie M. Homostatic compositions of polyacids and polyalkylene oxides and methods for their use
KR20030085522A (en) * 2001-01-25 2003-11-05 니코메드 파르마 에이에스 Carrier with Solid Fibrinogen and Solid Thrombin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0332677A (en) * 1989-06-30 1991-02-13 Yoshihiko Shimizu Vein closing material for imparting phlogistic and clotting property
US20020010150A1 (en) * 2000-04-28 2002-01-24 Cortese Stephanie M. Homostatic compositions of polyacids and polyalkylene oxides and methods for their use
KR20030085522A (en) * 2001-01-25 2003-11-05 니코메드 파르마 에이에스 Carrier with Solid Fibrinogen and Solid Thrombin

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9004918B2 (en) 2001-06-14 2015-04-14 Hemcon Medical Technologies, Inc. Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan
US9132206B2 (en) 2001-06-14 2015-09-15 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan
US8951565B2 (en) 2003-12-23 2015-02-10 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan
US9204957B2 (en) 2005-03-17 2015-12-08 Hemcon Medical Technologies, Inc. Systems and methods for hemorrhage control and or tissue repair
WO2007124433A1 (en) * 2006-04-20 2007-11-01 Crosslink-D Hemostatic compositions and methods for controlling bleeding
EP2026850A2 (en) * 2006-05-23 2009-02-25 Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
EP2026850A4 (en) * 2006-05-23 2012-09-05 Providence Health Sys Oregon Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
US8920514B2 (en) 2006-05-23 2014-12-30 Providence Health System—Oregon Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
US9205170B2 (en) 2008-05-02 2015-12-08 Hemcon Medical Technologies, Inc. Wound dressing devices and methods
US10086105B2 (en) 2008-10-06 2018-10-02 Providence Health System—Oregon Chitosan foam medical devices and methods
WO2010136872A3 (en) * 2009-05-25 2011-05-26 Pharcoterm S.R.L. Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination
US9918937B2 (en) 2013-01-30 2018-03-20 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
EP2950822A4 (en) * 2013-01-30 2016-10-19 Daewoong Co Ltd Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
CN103446619A (en) * 2013-08-19 2013-12-18 青岛中腾生物技术有限公司 Novel absorbable hemostatic material
US10004690B2 (en) 2014-01-21 2018-06-26 Utah-Inha Dds & Advanced Therapeutics Research Center Administrable microparticles in vivo through medical conduit
WO2021167963A1 (en) * 2020-02-18 2021-08-26 Boston Scientific Scimed, Inc. Hemostatic compositions and related methods
CN115175710A (en) * 2020-02-18 2022-10-11 波士顿科学国际有限公司 Hemostatic compositions and related methods

Also Published As

Publication number Publication date
KR20060040329A (en) 2006-05-10

Similar Documents

Publication Publication Date Title
WO2006049463A1 (en) Hemostatic agent internally applied through endoscope and application method thereof
JP6893074B2 (en) Reagents used for repair or hemostasis of biological tissue damage and their applications
JP7012779B2 (en) Surgical method using purified amphipathic peptide composition
EP3228331B1 (en) Biocompatible hemostatic product and preparation method thereof
US9381270B2 (en) Mucosal tissue dressing and method of use
AU2014237970B2 (en) Adhesive medical products and methods for treating gastrointestinal lesions
CN105491966B (en) For removing the system of the formation gel of urethral calculus and/or urethral calculus fragment
EP2790709A1 (en) Hemostatic agents and methods of use
JP2022023110A (en) Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
CN112076341A (en) Self-curing self-adhesive digestive tract injury mucosa protective adhesive and application thereof
CN111298188A (en) Self-curing double-component ion and temperature double-sensitive digestive tract mucosa protective adhesive and application thereof
CN110075345B (en) Bi-component self-adhesive gastric mucosa protective adhesive suitable for spraying gastroscope on surface of gastric injury mucosa and application thereof
EP4110411A1 (en) Sprayable stimuli-responsive micro-hydrogels for adhesion prevention and enhanced tissue healing
US20190091374A1 (en) Crosslinking Submucosal Injectate System
WO2023163202A1 (en) Treatment member forming agent
US20210251890A1 (en) Hemostatic compositions and related methods
WO2008002178A1 (en) Biological polymer adhesive
Felger et al. Complications of Thyroid and Parathyroid Surgery and How to Avoid Them
RU2405464C1 (en) Method of stopping bleeding in case of acute ulcer and after polypectomy
CN115337469A (en) Medicinal coating of ligation device and preparation method thereof
KR20220043917A (en) Aqueous adhesive composition comprising silk fibroin protein modified with kosmotropic salt and method for preparing the same
CN116099059A (en) Injectable antibacterial fistula blocking hydrogel and preparation method thereof
RU2246266C1 (en) Method for sealing bronchus stump
Mann et al. SUTURE MATERIALS AND BASIC SUTURE PATTERNS
UA113102U (en) METHOD OF STOP AND PREVENTION OF Bleeding relapse in case of non-hazardous lesions of the gastrointestinal tract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTHING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC(EPO COMMUNICATIONS=> FORMS 1205A DATED 23.07.2007 AND 14.09.2007)

122 Ep: pct application non-entry in european phase

Ref document number: 05820417

Country of ref document: EP

Kind code of ref document: A1